82 FR 49215 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 204 (October 24, 2017)

Page Range		49215-49215
FR Document		2017-22967

Federal Register, Volume 82 Issue 204 (Tuesday, October 24, 2017)

[Federal Register Volume 82, Number 204 (Tuesday, October 24, 2017)]
[Notices]
[Page 49215]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-22967]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial 
Implementation Cooperative Agreement (U44).
    Date: November 17, 2017.
    Time: 1:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 5601 Fishers Lane, 
Rockville, MD 20892 (Telephone Conference Call).
    Contact Person: Vasundhara Varthakavi, Ph.D., DVM, Scientific 
Review Officer, Scientific Review Program, Division of Extramural 
Activities, Room 3E70, National Institutes of Health, NIAID, 5601 
Fishers Lane, MSC 9823, Bethesda, MD 20892-9823, (240) 669-5020, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: October 18, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-22967 Filed 10-23-17; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 204 / Tuesday, October 24, 2017 / Notices 49215

TABLE 1—Continued
Application No. Drug Applicant

ANDA 085720 ........ Meprobamate Tablets USP, 200 mg ........................................................ Do.
ANDA 085721 ........ Meprobamate Tablets USP, 400 mg ........................................................ Do.
ANDA 085778 ........ Hydroxyzine HCl Injection USP, 25 mg/mL .............................................. Do.
ANDA 086096 ........ Chlorpheniramine Maleate Injection USP, 10 mg/mL ............................... Do.
ANDA 086189 ........ Ergoloid Mesylates Sublingual Tablets USP, 0.5 mg ............................... Do.
ANDA 086598 ........ Nandrolone Decanoate Injection USP, 100 mg/mL .................................. Do.
ANDA 086795 ........ Chlorothiazide Tablets USP, 250 mg ........................................................ Do.
ANDA 087183 ........ Ergoloid Mesylates Sublingual Tablets USP, 1 mg .................................. Do.
ANDA 087296 ........ Chlorthalidone Tablets USP, 25 mg ......................................................... Do.
ANDA 087521 ........ Chlorthalidone Tablets USP, 50 mg ......................................................... Do.
ANDA 087772 ........ Prednisone Tablets USP, 50 mg .............................................................. Do.
ANDA 087979 ........ Chloroquine Phosphate Tablets USP, EQ 150 mg base ......................... Do.
ANDA 088030 ........ Chloroquine Phosphate Tablets USP, EQ 300 mg base ......................... Do.
ANDA 089042 ........ Procainamide HCl Extended-Release Tablets USP, 750 mg ................... Do.

Therefore, approval of the would constitute a clearly unwarranted confidential trade secrets or commercial
applications listed in table 1, and all invasion of personal privacy. property such as patentable material,
amendments and supplements thereto, Name of Committee: National Institute of and personal information concerning
is hereby withdrawn as of November 24, Allergy and Infectious Diseases Special individuals associated with the grant
2017. Introduction or delivery for Emphasis Panel; NIAID SBIR Phase II applications, the disclosure of which
introduction into interstate commerce of Clinical Trial Implementation Cooperative would constitute a clearly unwarranted
products without approved new drug Agreement (U44). invasion of personal privacy.
applications violates section 301(a) and Date: November 17, 2017.
Time: 1:00 p.m. to 4:00 p.m. Name of Committee: Center for Scientific
(d) of the Federal Food, Drug, and Review Special Emphasis Panel;
Agenda: To review and evaluate grant
Cosmetic Act (21 U.S.C. 331(a) and (d)). applications. International Research Ethics Training.
Drug products that are listed in table 1 Place: National Institutes of Health, 5601 Date: November 16, 2017.
that are in inventory on the date that Fishers Lane, Rockville, MD 20892 Time: 8:00 a.m. to 6:00 p.m.
this notice becomes effective (see the (Telephone Conference Call). Agenda: To review and evaluate grant
applications.
DATES section) may continue to be Contact Person: Vasundhara Varthakavi,
Place: National Institutes of Health, 6701
dispensed until the inventories have Ph.D., DVM, Scientific Review Officer,
Rockledge Drive, Bethesda, MD 20892.
been depleted or the drug products have Scientific Review Program, Division of
Contact Person: Karin F. Helmers, Ph.D.,
reached their expiration dates or Extramural Activities, Room 3E70, National
Scientific Review Officer, Center for
Institutes of Health, NIAID, 5601 Fishers
otherwise become violative, whichever Lane, MSC 9823, Bethesda, MD 20892–9823,
Scientific Review, National Institutes of
occurs first. Health, 6701 Rockledge Drive, Room 3148,
(240) 669–5020, varthakaviv@niaid.nih.gov.
MSC 7770, Bethesda, MD 20892, (301) 254–
Dated: October 18, 2017. (Catalogue of Federal Domestic Assistance 9975, helmersk@csr.nih.gov.
Leslie Kux, Program Nos. 93.855, Allergy, Immunology, Name of Committee: Center for Scientific
Associate Commissioner for Policy. and Transplantation Research; 93.856, Review Special Emphasis Panel; PAR16–121
Microbiology and Infectious Diseases Early-Stage Preclinical Validation of
[FR Doc. 2017–23046 Filed 10–23–17; 8:45 am]
Research, National Institutes of Health, HHS) Therapeutic Leads for Diseases of Interest to
BILLING CODE 4164–01–P
Dated: October 18, 2017. the NIDDK (R01).
Natasha M. Copeland, Date: November 16, 2017.
Time: 12:00 p.m. to 6:00 p.m.
DEPARTMENT OF HEALTH AND Program Analyst, Office of Federal Advisory
Agenda: To review and evaluate grant
HUMAN SERVICES Committee Policy.
applications.
[FR Doc. 2017–22967 Filed 10–23–17; 8:45 am] Place: National Institutes of Health, 6701
National Institutes of Health BILLING CODE 4140–01–P Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
National Institute of Allergy and Contact Person: Raul Rojas, Ph.D.,
Infectious Diseases; Notice of Closed DEPARTMENT OF HEALTH AND Scientific Review Officer, Center for
Meeting HUMAN SERVICES Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6185,
Pursuant to section 10(d) of the Bethesda, MD 20892, (301) 451–6319, rojasr@
Federal Advisory Committee Act, as National Institutes of Health
mail.nih.gov.
amended, notice is hereby given of the Name of Committee: Center for Scientific
Center for Scientific Review; Notice of
following meeting. Review Special Emphasis Panel; Member
The meeting will be closed to the Closed Meetings
Conflict: Macromolecular Structure and
public in accordance with the Pursuant to section 10(d) of the Function.
asabaliauskas on DSKBBXCHB2PROD with NOTICES

provisions set forth in sections Federal Advisory Committee Act, as Date: November 20, 2017.
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., amended, notice is hereby given of the Time: 1:00 p.m. to 6:00 p.m.
as amended. The grant applications and following meetings. Agenda: To review and evaluate grant
the discussions could disclose The meetings will be closed to the applications.
Place: National Institutes of Health, 6701
confidential trade secrets or commercial public in accordance with the Rockledge Drive, Bethesda, MD 20892
property such as patentable material, provisions set forth in sections (Telephone Conference Call).
and personal information concerning 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Contact Person: C-L Albert Wang, Ph.D.,
individuals associated with the grant as amended. The grant applications and Scientific Review Officer, Center for
applications, the disclosure of which the discussions could disclose Scientific Review, National Institutes of

VerDate Sep<11>2014 17:47 Oct 23, 2017 Jkt 244001 PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 E:\FR\FM\24OCN1.SGM 24OCN1

Document Created: 2018-10-25 10:10:55
Document Modified: 2018-10-25 10:10:55

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		November 17, 2017.
FR Citation		82 FR 49215

82 FR 49215 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 204 (October 24, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health